PMID- 31913730
OWN - NLM
STAT- MEDLINE
DCOM- 20201124
LR  - 20240330
IS  - 1521-0464 (Electronic)
IS  - 1071-7544 (Print)
IS  - 1071-7544 (Linking)
VI  - 27
IP  - 1
DP  - 2020 Dec
TI  - Study on the cellular internalization mechanisms and in vivo anti-bone metastasis 
      prostate cancer efficiency of the peptide T7-modified polypeptide nanoparticles.
PG  - 161-169
LID - 10.1080/10717544.2019.1709923 [doi]
AB  - Bone-metastasis prostate cancer (BMPCa)-targeting gene therapy is gaining 
      increasing concern in recent years. The peptide T7-modified polypeptide 
      nanoparticles for delivery DNA (CRD-PEG-T7/pPMEPA1) was prepared as our previous 
      study. However, the feasibility of CRD-PEG-T7/pPMEPA1 for BMPCa treatment, the 
      mechanisms underlying cellular uptake, anti-BMPCa effect, and administration 
      safety requires further research. LNCaP cells treated with endocytosis inhibitors 
      and excessive T7 under different culture condition were carried out to 
      investigate the mechanisms of cellular uptake of the CRD-PEG-T7-pPMEPA1. A 
      transwell assay was applied to evaluate the cell migration ability. Besides, the 
      tumor volume and survival rates of the PCa xenograft mice model were recorded to 
      estimate the anti-tumor effect. In addition, the weight profiles of the PCa 
      tumor-bearing mice, the blood chemistry, and the HE analysis of visceral organs 
      and tumor was conducted to investigate the administration safety of 
      CRD-PEG-T7/pPMEPA1. The results showed that PCa cellular uptake was decreased 
      after treating with excessive free T7, endocytosis inhibitors and lower 
      incubation temperature. Besides, CRD-PEG-T7/pPMEPA1 could inhibit the LNCaP cells 
      chemotaxis and tumor growth. In addition, the survival duration of the PCa 
      tumor-bearing mice treating with CRD-PEG-T7/pPMEPA1 was significantly prolonged 
      with any systemic toxicity or damage to the organs. In conclusion, this research 
      proposes a promising stratagem for treatment BMPCa by providing the biocompatible 
      and effective carrier for delivery DNA therapeutic agents.
FAU - Gu, Yongwei
AU  - Gu Y
AD  - Department of Pharmacy, Fujian University of Traditional Chinese Medicine, 
      Fuzhou, China.
AD  - School of Pharmacy, Second Military Medical University, Shanghai, China.
FAU - Chen, Xinmei
AU  - Chen X
AD  - Department of Pharmacy, Fujian University of Traditional Chinese Medicine, 
      Fuzhou, China.
FAU - Zhang, Haiyan
AU  - Zhang H
AD  - Department of Pharmacy, Fujian University of Traditional Chinese Medicine, 
      Fuzhou, China.
FAU - Wang, Heyi
AU  - Wang H
AD  - Department of Pharmacy, Inner Mongolia Medical University, Huhhot, China.
FAU - Chen, Hang
AU  - Chen H
AD  - Department of Pharmacy, Fujian University of Traditional Chinese Medicine, 
      Fuzhou, China.
FAU - Huang, Sifan
AU  - Huang S
AD  - Department of Pharmacy, Fujian University of Traditional Chinese Medicine, 
      Fuzhou, China.
FAU - Xu, Youfa
AU  - Xu Y
AD  - Shanghai Wei Er Biopharmaceutical Technology Co., Ltd, Shanghai, China.
FAU - Zhang, Yuansheng
AU  - Zhang Y
AD  - Shanghai Wei Er Biopharmaceutical Technology Co., Ltd, Shanghai, China.
FAU - Wu, Xin
AU  - Wu X
AD  - School of Pharmacy, Second Military Medical University, Shanghai, China.
AD  - Shanghai Wei Er Biopharmaceutical Technology Co., Ltd, Shanghai, China.
FAU - Chen, Jianming
AU  - Chen J
AD  - Department of Pharmacy, Fujian University of Traditional Chinese Medicine, 
      Fuzhou, China.
AD  - Department of Pharmacy, Inner Mongolia Medical University, Huhhot, China.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Drug Deliv
JT  - Drug delivery
JID - 9417471
RN  - 0 (Membrane Proteins)
RN  - 0 (Peptide Fragments)
RN  - 0 (Pmepa1 protein, mouse)
RN  - 0 (peptide T (4-8))
RN  - 106362-33-8 (Peptide T)
RN  - 30KYC7MIAI (Aspartic Acid)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - 94ZLA3W45F (Arginine)
RN  - K848JZ4886 (Cysteine)
SB  - IM
MH  - Animals
MH  - Arginine
MH  - Aspartic Acid
MH  - Bone Neoplasms/*prevention & control/*secondary
MH  - Cell Line, Tumor
MH  - Cell Movement
MH  - Cell Survival
MH  - Cysteine
MH  - Genetic Vectors/*chemistry/*pharmacology
MH  - Male
MH  - Membrane Proteins/genetics
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Nanoparticles/chemistry
MH  - Particle Size
MH  - Peptide Fragments
MH  - Peptide T
MH  - Polyethylene Glycols/chemistry
MH  - Prostatic Neoplasms/*genetics/*pathology
MH  - Tumor Burden
PMC - PMC6968257
OTO - NOTNLM
OT  - Gene therapy
OT  - administration safety
OT  - anti-tumor effect
OT  - bone-metastases prostate cancer
OT  - cellular internalization mechanisms
EDAT- 2020/01/09 06:00
MHDA- 2020/11/25 06:00
PMCR- 2020/01/08
CRDT- 2020/01/09 06:00
PHST- 2020/01/09 06:00 [entrez]
PHST- 2020/01/09 06:00 [pubmed]
PHST- 2020/11/25 06:00 [medline]
PHST- 2020/01/08 00:00 [pmc-release]
AID - 1709923 [pii]
AID - 10.1080/10717544.2019.1709923 [doi]
PST - ppublish
SO  - Drug Deliv. 2020 Dec;27(1):161-169. doi: 10.1080/10717544.2019.1709923.